LivaNova (NASDAQ:LIVN) Upgraded at Wolfe Research

Wolfe Research upgraded shares of LivaNova (NASDAQ:LIVN - Free Report) from a peer perform rating to an outperform rating in a research note issued to investors on Tuesday morning, Marketbeat reports. Wolfe Research currently has $60.00 price target on the stock.

A number of other analysts have also commented on the company. Barclays dropped their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Mizuho cut their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Wall Street Zen downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average target price of $59.29.

LivaNova Stock Down 3.0%

LivaNova stock traded down $1.30 during trading on Tuesday, hitting $41.88. 602,740 shares of the company were exchanged, compared to its average volume of 651,153. The company has a market capitalization of $2.28 billion, a P/E ratio of 99.71 and a beta of 0.84. The business's 50 day moving average is $38.77 and its 200 day moving average is $44.60. LivaNova has a 52 week low of $32.48 and a 52 week high of $61.94. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of LivaNova by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after purchasing an additional 316,993 shares in the last quarter. Capital Research Global Investors boosted its stake in LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after buying an additional 258,730 shares in the last quarter. AQR Capital Management LLC grew its position in LivaNova by 111.7% during the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock valued at $60,809,000 after acquiring an additional 829,115 shares during the last quarter. Dimensional Fund Advisors LP grew its position in LivaNova by 8.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after acquiring an additional 107,693 shares during the last quarter. Finally, Redmile Group LLC raised its stake in shares of LivaNova by 19.3% during the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock worth $48,326,000 after acquiring an additional 168,500 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.